TickerStat.com4basebio expands synthetic-DNA manufacturing for personalised mRNA medicines
4basebio announced an expansion of its DNA offering on 7 September 2026. Manufacturing changes The company has added suite capacity and enhanced process controls and quality systems across its Cambridge high-quality and current-GMP operations. The offering targets small, patient-specific batches, shorter turnaround times and rapid batch release for the DNA starting material used in personalised mRNA medicines. Commercial rationale Individualised treatments require a different production model fr
0